The Conference Forum announces Dr Crystal Mackall, Stanford University, as the latest addition to the keynote speaker lineup for the Immuno-Oncology 360º 2025 meeting.
NEW YORK, Nov. 27, 2024 /PRNewswire-PRWeb/ -- The Conference Forum announced that Dr Crystal Mackall, MD, FAAP, FAACR, Stanford University will keynote at the Immuno-Oncology 360º Summit (IO360°) on shaping the next era in cell therapy. The 11th annual IO360º meeting takes place March 24-26, 2025 at the Sheraton Boston Hotel in Boston, MA.
"As a pioneer in cell therapy, Dr Mackall will give her forward-looking perspective on breakthrough innovations in cell therapy, strategies to overcome complex therapeutic challenges, and how to steer the next generation of cancer treatments," said Kate Woda, Senior Director, IO360º.
Dr Mackall's cell therapy research was recently recognized by the U.S. Food and Drug Administration with a regenerative medicine advanced therapy designation for her work in CAR T therapy for diffuse midline gliomas – pediatric brain and spinal cord tumors that are typically incurable. In a clinical trial, the findings of which were published in November's Nature, nine of 11 patients saw neurological benefit, and one patient exhibited a complete response with no detectable traces of tumor.
Dr Mackall joins an All-Star Keynote & VIP Lineup that includes:
- Allogene's Executive Chairman and Co-Founder, Dr Arie Belldegrun, on Investments and Adopting to IO Market Dynamics
- Adaptimmune's Chief Medical Officer, Dr Elliot Norry, on the First FDA-Approved TCR Therapy for Solid Tumors
- FAU Erlangen-Nürnberg's VP of Research, Prof Dr Georg Schett, on CAR-T in Autoimmune Diseases
- Delphi Ventures Managing Partner and Stealth Oncology Company CEO/Co-Founder, Dr Deepa Pakianathan, on Designing Best-in-Class ADCs in IO
- Pfizer's Chief Strategy and Innovation Officer, Dr Andrew Baum, on Strategic Innovations and Industry Trends
"IO360 has become the premier immuno-oncology conference addressing all stakeholders of our ecosystem, particularly including the investment and biotech community in addition to the full spectrum of basic, translational and clinical research. We present practice-relevant data and discuss the key trends across the IO ecosystem," said Dr Axel Hoos, IO360º advisor and former CEO, Scorpion Therapeutics.
To learn more about IO360º, visit io360summit.com.
About Immuno-Oncology 360º:
IO360˚ is an annual conference that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.
About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.
Media Contact
Danny McCarthy, IO360°, (646) 350-2580, [email protected], https://io360summit.com/
SOURCE IO360°
Share this article